Protein-Protein Interactions in Human Disease, Part B

Erscheinungsjahr 2018
ISBN: 978-0-12-814342-1
Verlag: William Andrew Publishing

Buch, Englisch, 294 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 540 g

Protein-Protein Interactions in Human Disease, Volume 111, Part B, promotes further research and development in the protein interaction network in order to identify critical proteins involved in the etiology of human diseases and locate new protein targets for drug development. Thus, this volume is of considerable interest to protein chemists, pharmacologists, cell biologists, immunologists, structural biologists, computational biochemists and other researchers working in the field. In addition, these articles would be of great benefit to medical, biology and pharmacology students who specialize in this field.

Zielgruppe

<p>The aim of this volume is to promote further research and development in the protein interaction network in order to identify critical proteins involved in the etiology of human diseases and to identify new protein targets for drug development. Thus, this volume would be of considerable interest to protein chemists, pharmacologists, cell biologists, immunologists, structural biologists, computational biochemists and other researchers working in this field. Articles published here would also be of a great benefit to medical, biology and pharmacology students specializing in this field. </p>

Autoren/Hrsg.

Weitere Mitwirkende

Donev, Rossen

Fachgebiete

• Naturwissenschaften Biowissenschaften Proteinforschung
• Naturwissenschaften Biowissenschaften Biochemie (nichtmedizinisch)

Inhaltsverzeichnis

1. Homo- and Heterodimerization of Proteins in Cell Signaling: Inhibition and Drug DesignSitanshu S. Singh and Seetharama D. Jois2. Targeting Intramembrane Protein-Protein Interactions: Novel Therapeutic Strategy of Millions Years OldAlexander B. Sigalov3. Targeting the Architecture of Deregulated Protein Complexes in CancerEduard Stefan, Jakob Troppmair and Klaus Bister4. Multifaceted Nucleolin Protein and Its Molecular Partners in OncogenesisIva Ugrinova, Maria Petrova, Mounira Chalabi-Dchar and Philippe Bouvet5. Subcellular Targeting of Nitric Oxide Synthases Mediated by Their N-Terminal MotifsCarlos Costas-Insua, Javier Merino-Gracia, Clara Aicart-Ramos and Ignacio Rodríguez-Crespo6. Development of Protein-Protein Interaction Inhibitors for the Treatment of Infectious DiseasesAndrew F. Voter and James L. Keck7. Defining Pharmacological Targets by Analysis of Virus-Host Protein InteractionsManuel Llano and Mario A. Peña-Hernandez8. Investigating the Influence of Hotspot Mutations in Protein-Protein Interaction of IDH1 Homodimer Protein: A Computational ApproachD. Thirumal Kumar, P. Sneha, Jennifer Uppin, S. Usha and C. George Priya Doss9. Human Interactomics: Comparative Analysis of Different Protein Interaction Resources andConstruction of a Cancer Protein-Drug Bipartite NetworkJavier De Las Rivas, Diego Alonso-López and Mónica M. Arroyo

Über Autor(innen)

Donev, Rossen
Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.